DOI

10.1234/journal.2023.003

Keywords

Topics

Abstract

This paper presents novel approaches to vaccine development for emerging infectious diseases, highlighting recent advances in mRNA technology, viral vector platforms, and computational antigen design. We review case studies of rapid vaccine development during recent outbreaks and analyze factors contributing to successful deployment. The discussion includes considerations for global vaccine equity, cold chain requirements, and strategies for addressing viral variants. Recommendations are provided for creating sustainable vaccine development ecosystems that can respond rapidly to future pandemic threats.

References

• Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586(7830), 516-527.
• Graham, B. S., Mascola, J. R., & Fauci, A. S. (2018). Novel vaccine technologies: essential components of an adequate response to emerging viral diseases. JAMA, 319(14), 1431-1432.
• Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261-279.
• Pollard, A. J., & Bijker, E. M. (2021). A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology, 21(2), 83-100.
• Bloom, D. E., Black, S., & Rappuoli, R. (2021). Emerging infectious diseases: A proactive approach. Proceedings of the National Academy of Sciences, 118(5), e2021128118.